Temperature, ˚C | 40.6 ± 3,5 | 40.7 ± 6.6 | 40,5 ± 4,9 | 0.971 |
Respiratory rate, cpm | 23.7 ± 5.8 | 23.5 ± 5.8 | 23.9 ± 5.9 | 0.531 |
GCS | 10.6 ± 3.4 | 11.5 ± 3.0 | 9.9 ± 3.5 | <0.001 |
|
|
|
| <0.001 |
<8 | 49 (25.3) | 10 (11.4) | 39 (36.8) |
|
≥8 | 145 (74.7) | 78 (88.6) | 67 (63.2) |
|
Sp02, % | 90,8 ± 9.6 | 10.5 ± 3.5 | 11.6 ± 2.7 | 0.183 |
|
|
|
| 0.297 |
<90 | 44 (22.7) | 22 (25.0) | 22 (20.8) |
|
≥90 | 150 (77.3) | 66 (75.0) | 84 (79.2) |
|
Pupilla status, n (%) |
|
|
| 0.916 |
Bilateral myosis | 28 (14.4) | 13 (14.8) | 15 (14.2) |
|
Bilateral mydriasis | 22 (11.3) | 11 (12.5) | 11 (10.4) |
|
Motor deficiency, n (%) | 120 (61.9) | 57 (64.8) | 63 (59.4) | 0.270 |
Treatment, n (%) |
|
|
|
|
CCB (Nicardipine) | 113 (58.2) | 64 (72.7) | 70 (66.0) | 0.199 |
Insulin | 43 (22.2) | 0 (0.0) | 43 (40.6) | 0.007 |
Anti-seizure (Phenobarbital) | 71 (36.5) | 32 (36.4) | 39 (36.8) | 0.536 |
Anti-edematous (Mannitol) | 72 (37.1) | 26 (29.5) | 46 (43.4) | 0.003 |
Catecholamines | 33 (17.0) | 9 (10.2) | 24 (22.6) | 0.057 |
Mechanical ventilation | 50 (25.7) | 17 (19.3) | 33 (31.1) | 0.043 |